Frolich U, Leucht K, Grimm M, Foller S
Cancers (Basel). 2024; 16(20).
PMID: 39456617
PMC: 11506320.
DOI: 10.3390/cancers16203523.
Igissin N, Dyakov S, Telmanova Z, Kudaibergenova I, Ayaganov S, Turebayev D
Asian Pac J Cancer Prev. 2024; 25(9):3239-3249.
PMID: 39342603
PMC: 11700335.
DOI: 10.31557/APJCP.2024.25.9.3239.
Meng J, Jiang A, Lu X, Gu D, Ge Q, Bai S
Imeta. 2024; 2(4):e147.
PMID: 38868222
PMC: 10989995.
DOI: 10.1002/imt2.147.
Gao W, Li G, Zhu D, Niu Y
World J Clin Cases. 2024; 12(14):2332-2341.
PMID: 38765747
PMC: 11099415.
DOI: 10.12998/wjcc.v12.i14.2332.
Bi Z, Zhou J, Ma Y, Guo Q, Ju B, Zou H
Oncol Lett. 2024; 27(5):190.
PMID: 38495834
PMC: 10941079.
DOI: 10.3892/ol.2024.14323.
Development and validation of a nomogram for predicting the impact of tumor size on cancer-specific survival of locally advanced renal cell carcinoma: a SEER-based study.
Bai J, Lu Q, Wen Y, Shangguan T, Ye Y, Lin J
Aging (Albany NY). 2024; 16(4):3823-3836.
PMID: 38376430
PMC: 10929802.
DOI: 10.18632/aging.205562.
Screening for renal cell carcinoma in renal transplant recipients: a single-centre retrospective study.
Yohannan B, Sridhar A, Kaur H, DeGolovine A, Maithel N
BMJ Open. 2023; 13(9):e071658.
PMID: 37699639
PMC: 10503370.
DOI: 10.1136/bmjopen-2023-071658.
The prognostic value and immune correlation of IL18 expression and promoter methylation in renal cell carcinoma.
Wang X, Zhu W, Long Q, Chen E, Sun H, Li X
Clin Epigenetics. 2023; 15(1):14.
PMID: 36707882
PMC: 9883904.
DOI: 10.1186/s13148-023-01426-8.
Development and validation of nomograms predicting postoperative survival in patients with chromophobe renal cell carcinoma.
Li S, Zhu J, He Z, Ashok R, Xue N, Liu Z
Front Oncol. 2022; 12:982833.
PMID: 36452499
PMC: 9701834.
DOI: 10.3389/fonc.2022.982833.
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma.
Kaptein F, van der Hulle T, Braken S, van Gennep E, Buijs J, Burgmans M
JACC CardioOncol. 2022; 4(4):522-531.
PMID: 36444235
PMC: 9700252.
DOI: 10.1016/j.jaccao.2022.07.011.
Crisis Averted: Clinical T1b Renal Mass with Concurrent Arteriovenous Malformation and Renal Vein Thrombus.
Zekan D, Wasef K, Werner Z, Grammer R, Lombard C, Luchey A
Case Rep Urol. 2022; 2022:9176199.
PMID: 36439648
PMC: 9691311.
DOI: 10.1155/2022/9176199.
APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome.
Zeng W, Xiong G, Hua L, Hu Y, Guo X, Peng X
Sci Rep. 2022; 12(1):12406.
PMID: 35858961
PMC: 9300670.
DOI: 10.1038/s41598-022-16434-6.
Transient Receptor Potential Channel 1 Potentially Serves as a Biomarker Indicating T/TNM Stages and Predicting Long-Term Prognosis in Patients With Renal Cell Carcinoma.
Chen L, Shan G, Ge M, Qian H, Xia Y
Front Surg. 2022; 9:853310.
PMID: 35548183
PMC: 9081676.
DOI: 10.3389/fsurg.2022.853310.
METTL14-mediated N-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma.
Liu Z, Sun T, Piao C, Zhang Z, Kong C
Cell Commun Signal. 2022; 20(1):36.
PMID: 35305660
PMC: 8934459.
DOI: 10.1186/s12964-022-00831-5.
Metastatic Immune-Related Genes for Affecting Prognosis and Immune Response in Renal Clear Cell Carcinoma.
Sun S, Mao W, Wan L, Pan K, Deng L, Zhang L
Front Mol Biosci. 2022; 8:794326.
PMID: 35155566
PMC: 8832145.
DOI: 10.3389/fmolb.2021.794326.
Utilisation of virtual non-contrast images and virtual mono-energetic images acquired from dual-layer spectral CT for renal cell carcinoma: image quality and radiation dose.
Zhang X, Zhang G, Xu L, Bai X, Lu X, Yu S
Insights Imaging. 2022; 13(1):12.
PMID: 35072807
PMC: 8787008.
DOI: 10.1186/s13244-021-01146-8.
RHBDF2 gene functions are correlated to facilitated renal clear cell carcinoma progression.
Wang L, Liu X, Yang Y, Wang Y, Song Y, Gao S
Cancer Cell Int. 2021; 21(1):590.
PMID: 34736454
PMC: 8567583.
DOI: 10.1186/s12935-021-02277-0.
The inferior vena cava: anatomical variants and acquired pathologies.
Li S, Lee J, Hall J, Sutherland T
Insights Imaging. 2021; 12(1):123.
PMID: 34460015
PMC: 8405820.
DOI: 10.1186/s13244-021-01066-7.
Myc-associated zinc-finger protein promotes clear cell renal cell carcinoma progression through transcriptional activation of the MAP2K2-dependent ERK pathway.
Ren L, Qi J, Zhao A, Shi B, Zhang H, Wang D
Cancer Cell Int. 2021; 21(1):323.
PMID: 34183010
PMC: 8240279.
DOI: 10.1186/s12935-021-02020-9.
Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W, Shou J, Shi H, Wen L, Zhang H, Zheng S
Technol Cancer Res Treat. 2021; 20:15330338211019507.
PMID: 34032149
PMC: 8155752.
DOI: 10.1177/15330338211019507.